Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium Pharmaceutical (Nasdaq: COLL) reported its Q4 and full-year 2021 financial results, revealing a net loss of $25 million for Q4 and $71.5 million net income for the full year. The company anticipates 2022 revenues between $315 million and $330 million, driven by growth in Xtampza ER. They expect the BDSI acquisition to close in late Q1 2022, aiming for synergies exceeding $75 million. Despite challenges, Collegium ended 2021 with a cash balance of $186.4 million and achieved significant market share gains in Xtampza ER, with a 33% share of the oxycodone extended-release market.
Collegium Pharmaceutical (Nasdaq: COLL) announced an agreement to acquire BioDelivery Sciences International (BDSI) for $5.60 per share in cash, valuing BDSI at approximately $604 million. This acquisition, expected to close in Q1 2022, aims to enhance Collegium's portfolio in pain management and neurology, with estimated annual synergies of at least $75 million within 12 months. The transaction is anticipated to be accretive to earnings in 2022 and 2023, diversifying revenue sources and accelerating cash flow generation.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a conference call on February 24, 2022, at 4:30 p.m. ET to discuss its Q4 and full-year 2021 financial results. The call will be accessible via phone at (877) 407-8037 (U.S.) or (201) 689-8037 (International) and will also be available as a live audio webcast on their website. A replay will be posted approximately two hours after the event. Collegium is committed to advancing specialty pharmaceuticals aimed at improving patients' lives.
Collegium Pharmaceutical (Nasdaq: COLL) has reached a settlement framework to resolve 27 opioid-related lawsuits for a maximum payment of $2,750,000. This agreement aims to dismiss all pending cases while ensuring no admission of liability. The settlement, which awaits final approval, reflects the company's commitment to responsible pain management. Executive VP Shirley Kuhlmann expressed satisfaction with the resolution, indicating a focus on future operations free from this litigation burden.
Summary not available.
Collegium Pharmaceutical (Nasdaq: COLL) announced a $25 million Accelerated Share Repurchase (ASR) agreement with Jefferies LLC, part of a larger $100 million share buyback program authorized in August 2021. Upon completion of this ASR, Collegium will have approximately $52.2 million remaining under the buyback authorization. The ASR involves repurchasing around 1,026,694 shares at the $19.48 closing stock price as of November 12, 2021. This move reflects management's confidence in the business and commitment to enhancing shareholder value.
Collegium Pharmaceutical, a leader in responsible pain management, announced its participation in upcoming investor conferences. Management will attend the Jefferies London Healthcare Conference with virtual one-on-one meetings on November 18, 2021, and the Piper Sandler Annual Healthcare Conference featuring a virtual fireside chat on December 1, 2021. The fireside chat will be accessible via the Investor section of their website, with a replay available for 30 days post-event. For more information, visit Collegium's website.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced its participation in two upcoming investor conferences. The Jefferies London Healthcare Conference will host virtual one-on-one meetings on November 18, 2021. Additionally, the Piper Sandler Annual Healthcare Conference 2021 will feature a virtual fireside chat on December 1, 2021. The fireside chat will be webcast, and a replay will be available on the company's Investor section website for 30 days following the event.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported a net income of $8.0 million and adjusted EBITDA of $37.3 million for Q3 2021. The company's Board has authorized a $25 million accelerated share repurchase, part of a broader $100 million initiative. Collegium aims for record full-year revenue and profits, driven by a strong pain management portfolio. Xtampza ER reached a 32.5% market share in ER oxycodone, while the Nucynta franchise exceeded $150 million in revenue. The company updated its 2021 financial guidance, adjusting Xtampza ER expected revenues down to $130-$135 million.
Collegium Pharmaceutical (Nasdaq: COLL) will host a conference call and live webcast on November 4, 2021, at 4:30 p.m. ET to discuss its Q3 2021 financial results and provide a corporate update. Investors can join the call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers, referencing the "Collegium Pharmaceutical Q3 2021 Earnings Call." The webcast will be available on the company's website for replay shortly after the event.